10.09.20
Lilly's rheumatoid arthritis drug cuts COVID-19 deaths in trial,…
Arthritis drug improves survival odds for COVID-19 patients treated with remdesivir by 35%, NIH study finds An NIH trial tested a combination of Eli Lilly’s arthritis drug, barcitinib, and the antiviral remdesivir to treat COVID-19 Overall, those who got both drugs were 35% more likely to survive than those given remdesivir alone People on supplemental